ABSTRACT
Stentless aortic valves show excellent short-and mid-term results. After receiving a Toronto SPV valve, patients experience near-normal gradients and more rapid regression of left ventricular mass hypertrophy than seen with stented valves.1-12 These benefits may lead to improved patient survival. The focus is now on long-term outcomes. The success of the current generation of stentless aortic valves signals the beginning of a new era of prosthetic heart valves. These new valve designs will closely mimic the structure and function of the tissues they replace.
